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ABSTRACT 
Mesenchymal stem cells (MSCs) are being studied extensively due to their potential as 
a therapeutic cell source for many load-bearing tissues. Compression of tissues and the 
subsequent deformation of cells are just one type physical strain MSCs will need to 
withstand in vivo. Mechanotransduction by MSCs and their mechanical properties are 
partially controlled by the cytoskeleton, including vimentin intermediate filaments (IFs). 
Vimentin IF deficiency has been tied to changes in mechanosensing and mechanical 
properties of cells in some cell types. However, how vimentin IFs contribute to MSC 
deformability has not been comprehensively studied. Investigating the role of vimentin 
IFs in MSC mechanosensing and mechanical properties will assist in functional 
understanding and development of MSC therapies. In this study, we examined vimentin 
IFs’ contribution to MSCs’ ability to deform under external deformation using RNA 
interference. Our results indicate that a deficient vimentin IF network decreases the 
deformability of MSCs, and that this may be caused by the remaining cytoskeletal 
network compensating for the vimentin IF network alteration. Our observations 
introduce another piece of information regarding how vimentin IFs are involved in the 
complex role the cytoskeleton plays in the mechanical properties of cells.  
KEYWORDS: cytoskeleton, cell deformation, RNA interference, mechanotransduction 
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INTRODUCTION 1	
 2	
Mesenchymal stem cells (MSCs) have recently shown promise as a therapeutic cell 3	
source for the treatment of many diseases, including osteoarthritis 1,15. However, 4	
osteoarthritic cartilage presents a challenging environment for therapeutic MSCs, 5	
injected systemically or implanted within a biomaterial scaffold, due to the abnormal 6	
biochemical and mechanical environment 8,11. One characteristic of this mechanical 7	
environment is regular compression that deforms the tissue and chondrocytes, eliciting 8	
extracellular matrix protein expression 2,12,17,21,32,35. Response to mechanical stresses is 9	
partially governed by cellular mechanical properties. Changes in MSC mechanical 10	
properties have been found to be related to both their physical environment and 11	
differentiation potential 10,19,20,37. Mechanical properties and mechanotransduction are in 12	
part regulated by the cytoskeleton, consisting primarily of actin microfilaments, 13	
microtubules, and vimentin intermediate filaments (IFs) for cells of mesenchymal 14	
lineage 5,7,19,23,24,29,30,34,36. While their role in the pathogenesis of OA is still unknown, 15	
vimentin IFs have recently been found to be disrupted or dispersed in osteoarthritic 16	
chondrocytes 4,16. Notably, vimentin has also been shown to be downregulated in MSCs 17	
of osteoarthritic patients 27, which raises questions about the potential efficacy of 18	
autologous stem cell therapies for treatment of OA.  19	
 20	
The role of vimentin is  still being examined using a variety of techniques to decrease, 21	
disrupt, or collapse vimentin IFs, but it is clear that they are involved in modulating the 22	
mechanical properties of cells. In fibroblasts, mutations resulting in vimentin deficiency 23	
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have been linked to not only impaired migration, but also reduction of mechanical 1	
stability and stiffness of the cytoplasm 13,34. Further, in these cells, decreases in 2	
vimentin led to compromised ability for fibroblasts to contract collagen gels, which is 3	
critical for wound healing 7.  4	
 5	
Perinuclear collapse of vimentin networks in fibroblasts has also been induced using 6	
proteins, such as the oncogene simian virus 40 large T antigen 26 or one variant of 7	
mutated desmin 25. Oncogene expression-dependent collapse of the vimentin network 8	
in fibroblasts caused an increase in cellular stiffness, which supports vimentin IFs 9	
association with tumor invasion and tumor cell stiffness 26. IF collapse caused by 10	
mutated desmin revealed a complex distribution of cellular stiffness with increased 11	
cellular stiffness in regions of the collapsed vimentin and a decrease in stiffness in the 12	
remaining vimentin-deficient cytoplasm 25.  13	
 14	
Collapse of the vimentin network has also been induced by pharmacological inhibitors 15	
such as withaferin A 9, calyculin A 3, and acrylamide 5,14,30,33. In non-adherent cell 16	
populations or cells suspended in hydrogels have revealed decreases in cellular 17	
mechanical properties with the use of pharmacological inhibitors. Specifically, in 18	
chondrocytes and chondrocyte-like cells, disruption of vimentin networks using 19	
acrylamide resulted in decreased elastic moduli and viscoelasticity, as measured by 20	
atomic force microscopy and micropipette aspiration, as well as a decrease in 21	
deformability 5,14,30,33. Likewise, in T lymphocytes and natural killer cells, disruption of 22	
vimentin IFs caused a decrease in cellular stiffness 3,9.  23	
5	
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Much of the research investigating how vimentin intermediate filaments contribute to cell 2	
mechanics and function has been conducted in fibroblasts by introducing the expression 3	
of abnormal proteins or pharmacological inhibitors, which may have off target effects 4	
that can influence the measurement of cellular stiffness. However, whether vimentin IFs 5	
similarly affect the biophysical properties of MSCs has not been established and an 6	
improved understanding of how IFs are involved in mechanosensing and mechanical 7	
properties of MSCs will be valuable for interpreting outcomes from stem cell therapies. 8	
In this study, we examine the relationship between MSCs’ capacity to deform under 9	
external compression and the involvement of vimentin IFs using shRNA mediated RNA 10	
interference (RNAi). The aim is to investigate the effect of a decreased vimentin IF 11	
network on MSC deformability independent of effects from cell-substrate adhesion and 12	
long culture times. Our results suggest that a decrease in vimentin IFs paradoxically 13	
reduces the deformability of MSCs, potentially due to changes in the manner by which 14	
actin microfilaments and microtubules organize and function to resist loads.  15	
 16	
MATERIALS AND METHODS 17	
 18	
hMSC cell culture 19	
 20	
For initial lentiviral construct screening experiments, hMSCs from Lonza (Walkersville, 21	
MD) were expanded per manufacturer’s instructions and used at passage 5 (P.5). For 22	
subsequent experiments, population doubling level (PDL) 9 bone marrow derived 23	
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human mesenchymal stem cells (hMSCs) (RoosterBio; Frederick, MD) were expanded 1	
using RoosterBio Enriched Basal media supplemented with GTX Booster (RoosterBio) 2	
per manufacturer instructions and used at PDL 13-18 hMSCs (approximately 4-5 3	
passages). All subsequent subculture for lentiviral transduction and experimentation 4	
was completed using hMSC growth media: high glucose DMEM containing 4mM L-5	
Glutamine (Gibco) supplemented with 10% fetal bovine serum (FBS) (Gibco), 100 U mL 6	
-1 Penicillin Streptomycin (Gibco), 1% MEM non-essential amino acids (Gibco), and 4 7	
mM L-Glutamine (Gibco). Complete media exchange was completed every 2-3 days 8	
and the cells were maintained at 5% CO2 and at 37ᵒC.  9	
 10	
Lentivirus design and generation 11	
 12	
52 nt shRNA sense-loop-antisense sequences were designed and selected from human 13	
vimentin [Gen Bank: NM_003380] mRNA using the shRNA Designer through Biosettia, 14	
Inc. Single strand oligonucleotides were annealed and these double stranded oligos 15	
were then ligated into an inducible lentiviral RNAi vector conveying resistance to 16	
blasticidin and a TetO -H1 promoter following manufacturer instructions. This inducible 17	
system only allows shRNA transcription to take place in the presence of tetracycline 18	
antibiotics, specifically doxycycline. The pLV-RNAi kit and pLV-Pack Packaging mix 19	
(Biosettia) were used to generate the shRNA constructs and package into replication-20	
deficient lentivirus using HEK 293FT cells and Lipofectamine 2000.  Two sequences 21	
were evaluated, listed in Table 1, and a control shRNA lentiviral vector targeting the 22	
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LacZ gene was used (Biosettia). Virus-containing supernatants were collected 72 hr 1	
post transfection and stored at -80ᵒC until use.  2	
 3	
shRNA transduction 4	
 5	
We performed hMSC transduction with the shVim-vector for 24hrs at a multiplicity of 6	
infection (MOI) of 15. Cells transduced with a shLacZ-vector and non-transduced cells 7	
were used as controls. Transduction was completed in the presence of 6µg ml -1	8	
hexadimethrine bromide (Polybrene) (Sigma) to assist with transduction efficiency. 9	
Titered viral concentrations for an MOI of 15 were determined through a Quanti-IT 10	
PicoGreen Assay (Invitrogen). Two days post-infection, pure populations were selected 11	
using 12µg ml-1 Blasticidin for 4 days. Both shVim-hMSCs and shLacZ-hMSCs were 12	
cultured in the presence of 1µg ml -1 doxycycline to induce RNAi. Cells were cultured for 13	
7, 14, or 21 days on tissue culture plastic before being harvested to be assayed.  14	
 15	
Western blotting 16	
 17	
To quantify levels of vimentin protein translation, cells were transduced and induction 18	
carried out for 7, 14, and 21 days. Cells were harvested and resuspended in a lysis 19	
buffer (50 mM HEPES, 150 mM sodium chloride, 1% Triton X-100, 1 mM EDTA, 10 mM 20	
Na-pyrophosphate, 10% glycerin) supplemented with a 1:100 concentration of protease 21	
inhibitor cocktail (Fisher Scientific). Protein concentrations were determined using a 22	
modified Lowry assay with a Folin-phenol color reaction detected by a ND-1000 23	
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spectophotometer (Nanodrop). After sample removal, the supernatant was mixed at a 1	
concentration of 1:1 with a loading buffer (13% (v/v) Tris-HCl, 20% (v/v) glycerol, 4.6% 2	
(w/v) SDS, 0.02% (w/v) bromophenol blue, 200 mM dithiothreitol). Samples and a 3	
human vimentin protein positive control were subjected to SDS-PAGE using pre-cast 4	
Criterion Tris-HCl gels (BioRad). 293FT HEK cell lysate was used as a protein positive 5	
control for β-actin. Approximately 155µg of protein from each sample was loaded into 6	
the Criterion Tris-HCl gels. After SDS-PAGE, proteins were electrophoretically 7	
transferred to a polyvinylidene fluoride membrane and detected using a rabbit IgG anti-8	
human vimentin primary antibody (ThermoFisher) and Vectastain ABC-AmP for 9	
chromogenic detection. Detection of β-actin using a mouse IgG anti- human β-actin 10	
primary antibody was used as a loading control. Semi-quantitative analysis was 11	
completed using ImageJ (NIH) to determine band intensities and protein expression 12	
levels were determined relative to non-infected cells. For semi-quantitative analysis of 13	
vimentin protein expression levels, the top band of the cluster was used, as it aligns with 14	
the positive protein control.  15	
 16	
Immunofluorescence imaging 17	
 18	
To visualize decrease in translated vimentin protein in 2D cultures, vimentin RNAi was 19	
induced for 7 and 14 days. Sham control (shLacZ) samples were performed in parallel. 20	
As an additional control, non-transduced cells were subjected to the RNAi-inducing 21	
agent (1µg ml -1 doxycycline) for 14 days to determine its potential effects on 22	
cytoskeletal organization. Cells were fixed with 4% paraformaldehyde and 23	
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permeabilized using 0.1% Triton X-100.  Cells were labelled with either rabbit IgG anti-1	
human vimentin primary antibody (ThermoFisher) or mouse IgG anti-human tubulin 2	
primary antibody (Santa Cruz) and visualized with biotinylated (anti-rabbit IgG or anti-3	
mouse IgG) secondary antibodies (Vector) and fluorescein-labelled streptavidin 4	
(Vector). Actin filaments were then stained with Alexafluor 594 phalloidin (Invitrogen), 5	
and the nucleus labelled with DAPI (Invitrogen). Fluorescence images were taken at 6	
100x magnification with an Olympus IX81 microscope.   7	
 8	
To visualize the cytoskeleton antibodies in agarose gels, vimentin RNAi was induced for 9	
14 days before being harvested. Sham control (shLacZ) samples were performed in 10	
parallel. Cells were then resuspended in 4% (w/v) agarose and pipetted into a 6mm x 11	
3mm diameter mold, followed by overnight fixation in 4% paraformaldehyde. These 12	
were infiltrated with 30% sucrose, embedded in Tissue-Tek O.C.T compound (Sakura), 13	
and then stored at -80ᵒC until sectioning. Frozen sections (20 µm) were created using 14	
an HM550 series cryostat (Richard Allen Scientific). These sections were labelled with 15	
either rabbit IgG anti- human vimentin primary antibody (ThermoFisher) or rabbit IgG 16	
anti-human tubulin primary antibody (Abcam) and visualized with biotinylated anti-rabbit 17	
IgG secondary antibodies (Vector) and fluorescein-labelled streptavidin (Vector). In 18	
additional sections, actin filaments were stained with Alexafluor 488 Phalloidin 19	
(Invitrogen) and the nucleus stained using Slow Fade Gold anti-fade reagent with DAPI 20	
(Invitrogen). Confocal fluorescence images were taken at 600x magnification with a 21	
Nipkow (spinning) disk-equipped Olympus IX81 microscope. Confocal Z-stacks (1 µm 22	
slices) of the entire cells were taken and projected into a single image for analysis.  23	
10	
	
Fluorescence intensity of labelled proteins was quantified using Image J (NIH) 22. Cells 1	
were manually traced and corrected total cell fluorescence intensity measurements per 2	
cell area were calculated using the following equation: corrected total cellular 3	
fluorescence (CTCF) = (Integrated Density – (Area of selected cell x mean fluorescence 4	
of background reading)) / Cell Area (pixels). Data are shown as mean CTCF + s.e.m.  5	
 6	
Cell deformation 7	
 8	
To measure cell deformation, after 14 days of inducing vimentin (and LacZ) RNAi cells 9	
were incubated with Cell Tracker Green CMFDA (Invitrogen) to stain the cell cytoplasm. 10	
Subsequently, 300-400k cells were resuspended in 2% (w/v) or 4% (w/v) agarose and 11	
pipetted into a 6mm x 6mm x 10mm mold. After gels solidified, they were placed into a 12	
custom microscope-mounted micrometer-controlled deformation device 33. This process 13	
took at least two hours from time of trypsinization. Samples were then subjected to 0, 14	
10, and 20% uniaxial bulk compressive strain. Fluorescence images of cells were 15	
generated at 400x magnification and cell diameters in the loading direction and 16	
perpendicular to the loading direction were measured using ImageJ (NIH). Analysis was 17	
performed similar to a previously study 33. Aspect ratios (ARs) were calculated as cell 18	
diameter in the loading direction/ cell diameter perpendicular to load, and the deformed 19	
population ARs were then normalized to the undeformed population ARs. Data are 20	
shown as mean normalized aspect ratio ± standard deviation. 21	
 22	
Cytoskeletal disruption 23	
11	
	
 1	
To determine the effect of microfilament and microtubule disruption on the shVim-hMSC 2	
and shLacZ-hMSC deformability, after 14-15 days of RNAi induction cells were 3	
incubated with CMFDA live cell tracker (Invitrogen). Afterward 300-400k cells were 4	
resuspended in 4% (w/v) agarose and pipetted into a 6mm x 6mm x 10mm mold. 5	
Following encapsulation and prior to deformation, cell-agarose constructs were 6	
incubated with either 20 µM colchicine or 9.85 µM cytochalasin D for 3 h in 37ᵒC at 5% 7	
CO2 to disrupt microtubules or actin microfilaments, respectively 33. Agarose blocks 8	
were subjected to strain and the images analyzed, as described above. Data are shown 9	
as mean aspect ratio + standard deviation.   10	
 11	
Statistical Analysis 12	
 13	
Statistical analyses for all studies were performed using non-parametric Kruskal-Wallis 14	
tests followed by a Mann-Whitney post-hoc for pairwise analysis using the statistical 15	
software SPSS. Statistical significance was set to a = 0.05.  16	
 17	
RESULTS 18	
 19	
Inducible lentiviral shRNA mediated knockdown of vimentin expression in hMSCs 20	
 21	
Initially, two shRNA vectors (Table 1), designed using different locations within the 22	
gene, were assessed for effectiveness in decreasing vimentin expression over 14 days 23	
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in the presence of 1 µg ml -1 doxycycline, the highest recommended dose. Because 1	
shVim1 yielded greater RNAi than shVim2 (Figure 1A), it was used for all subsequent 2	
experiments and is henceforth referred to as shVim. Cultures of shVim-transduced 3	
hMSCs exhibited a 40-60% decrease in vimentin expression, as shown by Western blot 4	
in the initial screen and in experiments to further characterize the vimentin knockdown 5	
by shVim (Figure 1A, 1B). A decrease in vimentin protein was visible as seen by 6	
immunofluorescence in cells seeded on tissue culture plastic and in agarose hydrogels 7	
(Figure 1C, 1D). Visually, we confirmed that 1 µg ml -1 doxycycline had negligible effect 8	
on the organization of vimentin, tubulin and F-actin in 2-D culture (Figure 1E).  Based on 9	
these results, it was determined that inducing RNAi for at least 14 days sufficiently 10	
knocked down vimentin protein levels, and this minimum induction period was used for 11	
all subsequent experiments. 12	
 13	
Vimentin knockdown reduces hMSC deformability  14	
 15	
Knockdown of vimentin expression over 14 days resulted in decreased deformability of 16	
cells compared to both non-transduced hMSCs and shLacZ hMSCs in 4% agarose 17	
hydrogels. Compression of shVim-hMSCs yielded significantly higher normalized aspect 18	
ratios (Figure 2A), or smaller deformations, compared to non-transduced hMSCs at 19	
10% (p=0.003) and 20% (p<0.0005) strain (Figure 2B), as well as compared to shLacZ-20	
hMSCs at 20% strain (p<0.0005). We found no significant difference between shLacZ-21	
hMSCs and non-transduced hMSCs, indicating that lentiviral transduction did not 22	
significantly affect cellular deformability (10%, p=0.528; 20%, p=0.913; Figure 2B). 23	
13	
	
Interestingly, no significant difference was observed between any of the groups during 1	
deformation within the 2% agarose gels (10%, p=0.182; 20% p=0.093; Figure 2C). 2	
Further, it was found that doxycycline treatment itself did not convey any resistance to 3	
the hMSCs (Figure 2D). After 14 days of 1 µg ml -1 doxycycline treatment, no significant 4	
difference in deformation was observed between untreated and treated hMSCs in 4% 5	
agarose gels in any strain group (10%, p=0.929; 20%, p=0.383).   6	
 7	
Functional role of actin filaments, but not microtubules, is altered by vimentin 8	
knockdown 9	
 10	
To determine whether the reduced deformability of shVim-hMSCs was caused by 11	
changes in the actin or microtubule network, we exposed transduced cells seeded in 12	
4% agarose to either cytochalasin D or colchicine, respectively. The non-transduced 13	
hMSCs sample group was not included in this experiment, because these cells were 14	
found to have no significant difference in deformability compared with shLacZ-hMSCs 15	
(Figure 2). Comparisons in this experiment focused only on the effect of vimentin 16	
knockdown to the sham (shLacZ) control. After disruption of the microtubule network, 17	
shVim-hMSCs remained significantly less deformable at both 10% (p=0.007) and 20% 18	
(p=0.001) strain compared to shLacZ-hMSCs (Figure 3A). In contrast, disrupting the 19	
actin microfilament network resulted in comparable cell deformations between shVim-20	
hMSCs and shLacZ-hMSCs (Figure 3B). Normalized aspect ratios were still slightly 21	
higher for shVim-hMSCs compared to shLacZ-hMSCs, but no longer significant at both 22	
10% (p=0.164) or 20% strain (p=0.215).   23	
14	
	
 1	
Cytoskeletal organization and quantity in agarose embedded hMSCs 2	
 3	
To further investigate the involvement of the actin or tubulin networks in the deformation 4	
of shRNA transduced cell populations, cytoskeletal protein content was semi-5	
quantitatively determined from fluorescence microscopy of non-deformed cells.  It was 6	
found that shVim-hMSCs and shLacZ-hMSCs did not have statistically significant 7	
differences in fluorescence intensities of F-actin staining (p=0.267) (Figure 4). However, 8	
the microtubule network fluorescence intensity was significantly lower in the shVim-9	
hMSCs compared to the shLacZ-hMSCs (p=0.01) (Figure 4).  10	
 11	
 12	
 13	
DISCUSSION 14	
 15	
Recently, studies have found vimentin IFs to be disrupted in chondrocytes and even in 16	
MSCs harvested from osteoarthritic bone marrow 4,16,27.  Because mechanical loading is 17	
a strong regulator of cell behavior, we investigated how an altered vimentin network 18	
affects deformation of hMSCs during loading of agarose constructs. As a major 19	
component of the cytoskeleton, vimentin IFs are involved in the cellular response to 20	
mechanical loading and in modulating cellular mechanical properties. However, 21	
extracellular matrix and substrate stiffness also introduce changes in cell shape and 22	
15	
	
cytoskeletal tension via adhesion complexes 20. Thus, the mechanical behavior of a cell 1	
is highly complex and context-dependent. 2	
 3	
In this study, we focused on the deformation of MSCs in an experimental system that 4	
minimizes the ability for cells to interact physically with their surrounding 5	
microenvironment. As MSCs are not habitually unattached to extracellular matrix, this 6	
study provides a snapshot of the intrinsic deformability of undifferentiated MSCs. To 7	
prevent cell-matrix interactions, which would confound measurements of intrinsic 8	
deformability, we examined deformation of cells embedded in agarose hydrogels 9	
without allowing for extended culture time, as previously described 33.  10	
 11	
Contrary to expectations, our experiments showed that in 4% agarose hydrogels MSCs 12	
with decreased vimentin expression are more resistant to deformation compared to 13	
control cells. In an attempt to elucidate the mechanism behind this phenomenon, we 14	
additionally disrupted either actin microfilaments or microtubules. Although cells were 15	
generally more deformable with either treatment, only disruption of actin microfilaments 16	
eliminated the difference in deformability between shLacZ and shVim cells. That 17	
vimentin-deficient MSCs maintained a significantly greater resistance to deformation 18	
with microtubule disruption suggests a less prominent role for microtubules. Semi-19	
quantitative measurement of the fluorescence intensity of immunostaining for F-actin 20	
and tubulin yielded further insight. Since actin fluorescence was unchanged, 21	
microfilament organization rather than quantity may be involved in the decreased 22	
deformability. The lower fluorescence intensity of the tubulin in shVim-hMSCs implies 23	
16	
	
that the decrease in microtubules and organization of the actin microfilaments may work 1	
cooperatively to enhance resistance to cell deformation. 2	
 3	
One obvious limitation of our RNAi approach is that vimentin IF expression is not 4	
completely ablated, unlike in fibroblasts isolated from vimentin null mice 7,34. On the 5	
other hand, our approach precludes any compensatory mechanisms that cells may 6	
develop physiologically in a knockout animal. Because vimentin continued to be 7	
expressed, albeit at a decreased level, we did not observe a complete collapse in the IF 8	
network with vimentin-silencing, as has been reported with acrylamide treatment 5,30. It 9	
is possible that the remaining vimentin network consists primarily of larger filaments, 10	
rather than the more diverse network of larger and smaller filaments that might support 11	
that strain normally. While large filaments were not observed in the immunostaining, 12	
Western blots did show a decrease in the smaller fragments in the knockdown cells 13	
compared to the control cells (Figure 1B).  14	
 15	
The increased resistance to deformation that we observed in the MSCs with decreased 16	
vimentin appears to contradict much of the literature in this area. Whole cell deformation 17	
experiments using chondrocytes and immune cells with chemically disrupted vimentin 18	
networks have resulted in mechanically less stiff and more deformable cells 3,5,9,14,30, 19	
though it is questionable how specific these treatments are for a given cytoskeletal 20	
target. Likewise in anchored vimentin-deficient fibroblasts, torsional loads applied via 21	
cell adhesions resulted in decreased stiffening or cytoplasmic rupture, suggesting that 22	
without vimentin, cells are mechanically unstable and unable to stiffen in response to 23	
17	
	
load 7,34. It is not clear at this time how much our unexpected findings might be 1	
explained by the lack of cell-matrix attachment and the 3D hydrogel microenvironment 2	
of our experimental system.  3	
 4	
Other studies, however, observed trends that are consistent with our results. One study 5	
reported a decrease in compressibility of acrylamide-treated chondrocytes 23. The 6	
authors postulated that vimentin IFs act as tensional elements preventing elongation 7	
orthogonal to the direction of compression, while microtubules prevent the compression 8	
of cells along the loading axis. Our data suggest that the actin microfilaments may play 9	
a more significant role in the resistance to deformation in the presence of a diminished 10	
vimentin network. Interestingly, dose-dependency of acrylamide treatment can also 11	
affect mechanical properties, implying a nonlinear relationship between the organization 12	
of vimentin and any change in cellular mechanical properties 30. Disruption of vimentin 13	
in chondrocytes using acrylamide was found to affect mechanical properties measured 14	
by micropipette aspiration only at high concentrations 30. Further, we have shown 15	
previously that chondrogenic hMSCs treated with this same high concentration of 16	
acrylamide trended toward increased deformability, but without statistically significant 17	
results 33. In this study, we did not observe a complete collapse of the vimentin network, 18	
and this could be why we see a dissimilar response to deformation in vimentin-deficient 19	
MSCs.   20	
 21	
One critical parameter of this study is the choice of culture duration in the agarose 22	
hydrogel. Without significant culture time, cells would not be able to develop adhesion 23	
18	
	
moieties that could subvert the deformation results. It has been observed that 1	
cytoskeletal proteins will undergo reorganization over chondrocyte culture time in 2	
agarose hydrogels over the timescale of days 18, implying that the cytoskeletal 3	
organization is dynamic over time. Here, we allowed a brief recovery after transfer to 3D 4	
culture in an attempt to capture an environment that simulates how vimentin may be 5	
involved in mechanosensing when hMSCs are first placed into a carrier biomaterial for 6	
therapy just prior to implantation. However, observations of cellular deformability at 7	
different stages in culture could provide more information about cell deformability and 8	
how microtubules and actin microfilaments reorganize to compensate for a less robust 9	
vimentin network over time. Further, longer culture periods would allow insight into 10	
changes in cellular phenotype due to 3-D culture, and changes in cellular behavior with 11	
the deposition of extracellular matrix. 12	
 13	
The mechanical loads experienced by hMSCs in our experimental system are 14	
analogous to inclusions that deform within a loaded bulk porous material, which 15	
compounds the complexity of factors – beyond those associated with the cytoskeleton – 16	
that contribute to the cell deformation results. On a superficial level, the measurements 17	
that were made using 2% and 4% agarose can provide some insight into the balance of 18	
stiffness between cells and their surrounding material. In 2% agarose, cells deformed 19	
less across all groups than in 4% agarose, whose modulus is roughly five times that of 20	
2% 6. It is possible that, due to the lower modulus of 2% agarose, cells were not 21	
subjected to sufficiently high compressive loads to resolve differences between shVim 22	
and shLacZ deformabilities. Delving deeper, some studies have shown differences in 23	
19	
	
cytoskeletal organization with different agarose concentrations 28.  Further, the non-1	
linear mechanics of the cells might be distinct between shVim and shLacZ MSCs, where 2	
deformation may be similar under low load, but distinct at high load. Our previous work 3	
on chondrogenic hMSCs deficient in type VI collagen 31 is one example of such 4	
behavior.  5	
 6	
Some important aspects of cell deformation that we were not able to explore in this 7	
study include potential anisotropy of cell deformation, which would require more time 8	
consuming confocal imaging and 3D strain analysis of cells, as well as the possibility of 9	
discontinuities at the cell-gel interface due to differential stiffnesses that could interfere 10	
with analysis of cellular deformation. A more rigorous mechanical analysis of how cell 11	
deformability is governed in this complex system is certainly warranted. In this particular 12	
study, we chose a more straightforward approach to characterizing cell deformation in 13	
order to collect sufficient data for statistical comparisons between treatment groups. 14	
 15	
While deformability measured by whole cell compression in 3D and stiffness 16	
measurements of anchored cells on a planar substrate yield different mechanical 17	
property relationships, it may be possible to relate the two sets of characteristics with 18	
further investigation. It has been speculated that the reduced mechanical stability 19	
observed in vimentin negative fibroblasts may not necessarily be directly correlated with 20	
cellular flexibility, implying that their ability to withstand large deformations, e.g. 21	
migration through small pores, could be impaired 7. We have also observed impaired 22	
chemotactic migration in the vimentin knockdown MSCs and further found that robust 23	
20	
	
vimentin networks may be required for migration through small pores (unpublished 1	
data). Further analysis of this phenomenon may shed light on the relationship between 2	
our observed deformation behavior in unanchored cells and cells experiencing 3	
mechanical stimuli due to adhesion and cytoskeletal remodeling during migration.  4	
 5	
One variable of this study that has not been systematically studied in stem cells is MOI 6	
used for lentiviral transduction and its potential effects on cellular physiology. In order 7	
for us to achieve the desired knockdown of a gene as robustly expressed as vimentin, a 8	
relatively high MOI was required. Our previous studies using lentivirus-mediated RNAi 9	
in hMSCs had shown no detrimental effects on differentiation 31, but those prior 10	
experiments had used lower MOI. Though we did not observe any overt differences in 11	
morphology in any cells used for this present study, it is possible that other aspects of 12	
stem cell function may have been affected, independent from decreased vimentin. 13	
There has been some anecdotal evidence that MOI-dependent effects may be 14	
important. 15	
 16	
This study reveals a unique relationship between vimentin IFs and MSCs’ capacity to 17	
deform due to external whole cell compression. Our observations suggest that 18	
deformability of MSCs is dependent on the robustness of the vimentin IF network in 19	
unanchored cells. Varying expression and organization of vimentin in healthy and 20	
diseased cells may affect the mechanical properties, and consequently the 21	
mechanotransduction, of these cells. Literature suggests that vimentin disruption or 22	
absence is present in osteoarthritic chondrocytes and even mesenchymal stem cells 23	
21	
	
from osteoarthritic patients, but it is not yet clear if this change is a symptom of the 1	
developing disease environment or an early actor in disease progression. In addition to 2	
examining vimentin’s role in the intrinsic properties of MSCs in agarose hydrogels, this 3	
study sheds initial light onto changes to mechanical properties that may occur to hMSCs 4	
due to an abrogated vimentin network that may be relevant in a cell therapy 5	
environment. Our observations introduce another variable and piece of information in 6	
understanding how IFs are involved in cellular mechanical properties.  7	
 8	
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Table 1. shRNA sequences screened for effective vimentin knockdown in hMSCs. 
Grey indicates overhang or loop shRNA 
Sequence	Name Sequence 
shVim1 5'-AAAAGGCAGAAGAATGGTACAAATTGGATCCAATTTGTACCATTCTTCTGCC-3' 
shVim2 5'-AAAAGGAATAAGCTCTAGTTCTTTTGGATCCAAAAGAACTAGAGCTTATTCC-3' 
Neg.	Control	(LacZ) 5’-GCAGTTATCTGGAAGATCAGGTTGGATCCAACCTGATCTTCCAGATAACTGC-3’ 
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FIGURE LEGENDS 
Figure 1. Characterization of vimentin knockdown in hMSCs. A. Two lentiviral 
vectors were screened using western blots and immunostaining on Day 14. In Western 
blots, ‘+Cntl’ is a purified vimentin protein positive control for Vim and a 293FT HEK cell 
lysate for B-Act. Scale bar: 50µm. B. Characterization of knockdown by Western blot on 
days 7, 14, and 21 of shRNA induction. ‘+Cntl’ is purified vimentin protein for Vim and 
293FT HEK cell lysate for B-Act. C. Observation of vimentin knockdown by 
immunostaining on days 3, 7, and 14 of shRNA induction; vimentin (green), F-actin 
(red), nucleus (blue). Scale bar: 50µm. D. Observation of vimentin knockdown in 
agarose hydrogel; vimentin (green), nucleus (blue). Scale bar: 50µm. E. Effect of 1ug ml 
-1 doxycycline treatment on cytoskeletal proteins of control, non-transduced, hMSCs. 
Scale bar: 50µm. 
Figure 2. Cell Deformation of Vimentin-deficient hMSCs. Normalized aspect ratios of 
cells subjected to 0%, 10%, or 20% strain. A. Deformation of control, non-transduced, 
hMSCs, shLacZ-hMSCs, shVim-hMSCs in 4% agarose hydrogels. B. Deformation of 
control, non-transduced, hMSCs, shLacZ-hMSCs, shVim-hMSCs in 2% agarose 
hydrogels.  C. Deformation of control, non-transduced, hMSCs with or without treatment 
with 1µg ml -1 doxycycline for 14 days. All data are expressed as mean aspect ratio ± 
SD. Asterisks represent statistically significant differences (p < 0.05). 
Figure 3. Effect of Cytoskeletal Disruption on Cell Deformation. Normalized aspect 
ratios of shVim-hMSCs and shLacZ-hMSCs subjected to 0%, 10%, or 20% strain after 
chemical disruption of actin microfilaments or tubulin microtubules. A.  Deformation of 
shLacZ-hMSCs and shVim-hMSCs after actin microfilament disruption  B. Deformation 
of shLacZ-hMSCs and shVim-hMSCs after microtubule disruption All data are 
expressed as mean aspect ratio ± SD. Asterisks represent statistically significant 
differences (p< 0.05). 
Figure 4: F-actin microfilament and Tubulin microtubule fluorescence intensity in 
shVim-hMSCs and shLacZ-hMSCs. Fluorescent intensity measurements of shLacZ-
hMSCs and shVim-hMSCs stained for F-Actin  and tubulin. All data are expressed as 
CTCF ± s.e.m. Asterisks represent statistically significant differences (p < 0.05). Scale 
bar: 50µm. 
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